Compare Summit Therapeutics Inc (SMMT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Yum China Holdings Inc trades at $42.34 (market cap $14.74B). The key difference: Summit Therapeutics Inc and Yum China Holdings Inc are close in size by market cap, and Yum China Holdings Inc pays a 2.68% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | YUMC | |
|---|---|---|
Market Cap | $13.79B | $14.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $57.95 |
52-Week Low | $12.43 | $40.18 |
Enterprise Value | $13.11B | $15.65B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
YUMC trades at $43.34, down 0.6% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth, reaching $11.8B in 2025, with a net income margin of 7.84%. Recent developments include the acquisition of Pizza Hut brand ownership in Mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive with strong analyst support—14 buy ratings and a projected 25.6% upside. Risks include competitive pressures and market volatility, but solid fundamentals and growth initiatives provide a compelling case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
